Smith & Nephew plc ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
9.9%projected annual EPS growth
Analyst Coverage
5analysts covering
FY Revenue (est.)
$6.5Bnext fiscal year
FY EPS (est.)
$2.22next fiscal year
Monitoring Framework
Key Performance Indicators
Underlying Revenue Growth Annually530.0%Target: around 6% for FY2026
Trading Profit Margin Annually1,970.0%Target: Expansion driven by RISE strategy
Free Cash Flow Annually840MTarget: around $800 million for FY2026
Watch Items
- U.S. Skin Substitutes Reimbursement ResetTrigger: CMS reimbursement policy changes and Advanced Wound Management division growthAction: Monitor quarterly Advanced Wound Management segment revenue and margin impact
- U.S. Knee Implant Sales RecoveryTrigger: U.S. knee implant sales growth lagging peers (fell 10.3% in Q1 2026)Action: Track market share recovery and CORI robotic-assisted surgical system installations
- RISE Strategy Execution and Cost SavingsTrigger: Delivery of $150 million incremental savings in 2026Action: Review semi-annual trading profit reports and operating margin progression
Research as of 2 Sep 2026